IPOs and Secondaries
IPOs and Secondaries Articles
Proteostasis Therapeutics expects to price less than 4 million shares in the range of $12 to $14 apiece in an initial public offering valued up to around $62 million.
Published:
Last Updated:
U.S. Foods has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Corvus Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Zynga is a near perfect example of a unicorn, although its demise is five years old. Investors no longer value such companies at their peaks.
Published:
Last Updated:
After markets failed to accept a single initial public offering (IPO) in January, the first week of February was a bit more propitious
Published:
Last Updated:
ArcelorMittal, the world's largest steelmaker, revealed fourth-quarter and full-year 2015 results Friday morning, and the view was anything but pretty.
Published:
Last Updated:
Mapi Pharma expects to price more than 3 million shares in the range of $15 to $17 in an initial public offering valued up to about $61 million.
Published:
Last Updated:
Very early Friday morning, independent oil and gas producer Hess announced that it had priced an underwritten offering of 25 million shares of common stock at $39 per share
Published:
Last Updated:
Quotient led the bulls going into Friday’s trading session on news of a secondary offering.
Published:
Last Updated:
Therapure Biopharma has announced that, due to current conditions in capital markets, it would postpone its initial public offering.
Published:
Last Updated:
BeiGene entered the market with a bang on Wednesday in its initial public offering priced at the high end of its expected range.
Published:
Last Updated:
Editas Medicine will price its nearly 6 million shares at $16 apiece in an initial public offering valued at more than $108 million.
Published:
Last Updated:
In its IPO, Beigene plans to offering more than 5 million American depositary shares in an expected price range of $22 to $24 apiece.
Published:
Last Updated:
Proteostasis Therapeutics expects to price more than 3 million shares in the range of $12 to $14 per share in an initial public offering is valued up to $62 million.
Published:
Last Updated:
Advanced Disposal Services shares are expected to price in the range of $20 to $22 per share, valuing the initial public offering at roughly $500 million.
Published:
Last Updated: